Insights on the use of biosimilars in the treatment of inflammatory bowel disease
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Insights on the use of biosimilars in the treatment of inflammatory bowel disease
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 23, Issue 11, Pages 1932
Publisher
Baishideng Publishing Group Inc.
Online
2017-03-19
DOI
10.3748/wjg.v23.i11.1932
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
- (2016) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- Biosimilars: A Multidisciplinary Perspective
- (2016) Majed Khraishi et al. CLINICAL THERAPEUTICS
- ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update
- (2016) Silvio Danese et al. Journal of Crohns & Colitis
- Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study
- (2016) Lisa J. T. Smits et al. Journal of Crohns & Colitis
- Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases
- (2016) Caroline Meyer Olesen et al. PHARMACOLOGY & THERAPEUTICS
- Development of biosimilars
- (2016) Ahmad AL-Sabbagh et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Ustekinumab in Crohn’s disease: evidence to date and place in therapy
- (2016) Tal Engel et al. Therapeutic Advances in Chronic Disease
- The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries
- (2015) Ashok Jha et al. ADVANCES IN THERAPY
- A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
- (2015) Jung-Yoon Choe et al. ANNALS OF THE RHEUMATIC DISEASES
- Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study
- (2015) Won Park et al. Expert Review of Clinical Immunology
- A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis
- (2015) Rajendrakumar H. Jani et al. International Journal of Rheumatic Diseases
- P505. Biosimilar but not the same
- (2015) Journal of Crohns & Colitis
- Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort
- (2015) Krisztina B. Gecse et al. Journal of Crohns & Colitis
- Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations
- (2015) J. Sieczkowska et al. Journal of Crohns & Colitis
- Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
- (2015) Yoon Suk Jung et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Efficacy and Safety of Antiintegrin Antibody for Inflammatory Bowel Disease
- (2015) Lianjie Lin et al. MEDICINE
- Biologic agents for IBD: practical insights
- (2015) Silvio Danese et al. Nature Reviews Gastroenterology & Hepatology
- Clinical trial development for biosimilars
- (2015) Rieke Alten et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Biosimilar safety factors in clinical practice
- (2015) Walter Reinisch et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe
- (2015) Fanni Rencz WORLD JOURNAL OF GASTROENTEROLOGY
- Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study
- (2015) Jørgen Jahnsen et al. Expert Review of Gastroenterology & Hepatology
- Biologics in inflammatory bowel disease: what are the data?
- (2015) Justin Côté-Daigneault et al. United European Gastroenterology Journal
- Immunogenicity of Anti-TNF-α Biotherapies: I. Individualized Medicine Based on Immunopharmacological Evidence
- (2015) Klaus Bendtzen Frontiers in Immunology
- Optimizing the use of biological therapy in patients with inflammatory bowel disease
- (2015) A. C. Moss Gastroenterology Report
- FRI0301 A Phase I Pharmacokinetics TRIAL Comparing PF-06438179 (A Potential Biosimilar) and Infliximab in Healthy Volunteers (Reflections B537-01)
- (2014) C. Udata et al. ANNALS OF THE RHEUMATIC DISEASES
- The challenge of indication extrapolation for infliximab biosimilars
- (2014) Brian G. Feagan et al. BIOLOGICALS
- Biosimilars: the science of extrapolation
- (2014) M. Weise et al. BLOOD
- Therapeutic drug monitoring in patients with inflammatory bowel disease
- (2014) Andres J Yarur WORLD JOURNAL OF GASTROENTEROLOGY
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
- (2013) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
- (2013) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- Inequities in access to biologic and synthetic DMARDs across 46 European countries
- (2013) Polina Putrik et al. ANNALS OF THE RHEUMATIC DISEASES
- Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease
- (2013) Brian G. Feagan et al. GASTROENTEROLOGY
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
- (2013) Remo Panaccione et al. GASTROENTEROLOGY
- Clinical pharmacology considerations in biologics development
- (2012) Liang Zhao et al. ACTA PHARMACOLOGICA SINICA
- Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
- (2012) I Ordás et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
- (2011) Natalie A. Molodecky et al. GASTROENTEROLOGY
- Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
- (2009) C H Seow et al. GUT
- The Direct and Indirect Cost Burden of Crohnʼs Disease and Ulcerative Colitis
- (2008) Teresa B. Gibson et al. JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started